Pfizer Venture Investments

Pfizer Venture Investments (Pfizer Ventures) is the corporate venture capital arm of Pfizer Inc., established in 2004 and headquartered in New York. The platform carries a $900 million total capital commitment, including a $600 million top-up announced in Q4 2021, and backs private companies at all stages of development with a strong bias toward early-stage therapeutics and platform technologies. Investment priorities mirror Pfizer's therapeutic areas: inflammation and immunology, internal medicine, oncology, and neuroscience, extending into platform technologies, diagnostics, drug delivery, pharmaceutical services, and healthcare IT. Roughly 25 percent of available capital, approximately $150 million, is explicitly earmarked for early-stage neuroscience investments. Across approximately 200 investments, Pfizer Ventures has built a concentrated neuroscience portfolio including Aquinnah, Autifony, Cortexyme, MindImmune, Mission Therapeutics, and Neuronetics. The platform leads rounds and invests globally, though deployments skew toward US-based companies. Recent notable investments include Curve Therapeutics (GBP 40.5 million Series A, led in February 2024), Enara Bio ($32.5 million Series B co-led with M Ventures in October 2024), Enlaza Therapeutics ($100 million Series A syndicate in September 2024), OTR Therapeutics ($100 million Series A for a Chinese biotech in June 2025), and Crossbow Therapeutics in March 2026 as the most recent disclosed investment. Pfizer Ventures serves as a strategic window on early-stage innovation across life sciences globally. Portfolio companies benefit not only from capital but also from Pfizer's regulatory expertise, clinical development networks, and therapeutic-area know-how, creating pathways to partnership, licensing, and acquisition that financial-only investors cannot offer.